AssetMark’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$47 Buy
+5
New +$40 ﹤0.01% 3720
2026
Q2
– Sell
-1
Closed -$8 – 3607
2026
Q1
$8 Buy
+1
New +$7 ﹤0.01% 3429
2025
Q4
– Sell
-48
Closed -$118 – 3421
2025
Q3
$118 Hold
48
– – ﹤0.01% 3108
2025
Q2
$127 Buy
+48
New +$129 ﹤0.01% 2923

Other funds holding IBRX

AssetMark's IBRX Position: Q3 2026 in Review

AssetMark opened a new position in ImmunityBio (IBRX) in Q3 2026: 5 shares worth $47. The stake represents ﹤0.01% of the portfolio and ranks #3720 among its holdings. This is a return to the name: AssetMark previously reported a position in IBRX as recently as Q1 2026.

AssetMark first reported a position in IBRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $127 in Q2 2025. 321 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • AssetMark held 5 shares of ImmunityBio worth $47 as of Q3 2026.
  • ImmunityBio was a new AssetMark position in Q3 2026.
  • ImmunityBio made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3720 holding.
  • AssetMark first reported a position in ImmunityBio in Q2 2025 and has held it in 4 quarters since.
  • AssetMark's ImmunityBio position peaked at $127 in Q2 2025.
  • 321 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.